WO2023086415A3 - Vlp immunotherapy combined with ablation - Google Patents

Vlp immunotherapy combined with ablation Download PDF

Info

Publication number
WO2023086415A3
WO2023086415A3 PCT/US2022/049450 US2022049450W WO2023086415A3 WO 2023086415 A3 WO2023086415 A3 WO 2023086415A3 US 2022049450 W US2022049450 W US 2022049450W WO 2023086415 A3 WO2023086415 A3 WO 2023086415A3
Authority
WO
WIPO (PCT)
Prior art keywords
ablation
vlp
virus
immunotherapy combined
combined
Prior art date
Application number
PCT/US2022/049450
Other languages
French (fr)
Other versions
WO2023086415A2 (en
Inventor
Nicole F. Steinmetz
Isabel NEWTON
Nicholas WEBSTER
Tyler MANDT
Hui Cai
Christine BOONE
Mansur GHANI
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2023086415A2 publication Critical patent/WO2023086415A2/en
Publication of WO2023086415A3 publication Critical patent/WO2023086415A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/18011—Comoviridae
    • C12N2770/18021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/18011—Comoviridae
    • C12N2770/18023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/18011—Comoviridae
    • C12N2770/18032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/18011—Comoviridae
    • C12N2770/18041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/18042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided herein is a novel, multimodal in situ vaccination approach to treat cancer by combining ablation with administration of the naturally occurring plant virus or virus-like particle (VLP) nanoparticles such as cowpea mosaic virus (CPMV), a plant virus-based immunoadjuvant.
PCT/US2022/049450 2021-11-10 2022-11-09 Vlp immunotherapy combined with ablation WO2023086415A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163277737P 2021-11-10 2021-11-10
US63/277,737 2021-11-10
US202163278457P 2021-11-11 2021-11-11
US63/278,457 2021-11-11

Publications (2)

Publication Number Publication Date
WO2023086415A2 WO2023086415A2 (en) 2023-05-19
WO2023086415A3 true WO2023086415A3 (en) 2023-07-06

Family

ID=86336692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/049450 WO2023086415A2 (en) 2021-11-10 2022-11-09 Vlp immunotherapy combined with ablation

Country Status (1)

Country Link
WO (1) WO2023086415A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210085777A1 (en) * 2014-11-07 2021-03-25 Case Western Reserve University Cancer immunotherapy using virus particles
WO2021108202A1 (en) * 2019-11-25 2021-06-03 The Regents Of The University Of California Modified viral therapeutics and uses thereof
US20210189396A1 (en) * 2019-12-20 2021-06-24 Case Western Reserve University Plant viral rna delivery nanoparticles and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210085777A1 (en) * 2014-11-07 2021-03-25 Case Western Reserve University Cancer immunotherapy using virus particles
WO2021108202A1 (en) * 2019-11-25 2021-06-03 The Regents Of The University Of California Modified viral therapeutics and uses thereof
US20210189396A1 (en) * 2019-12-20 2021-06-24 Case Western Reserve University Plant viral rna delivery nanoparticles and uses thereof

Also Published As

Publication number Publication date
WO2023086415A2 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
CA2762042A1 (en) Chimeric influenza virus-like particles comprising hemagglutinin
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
RU2013154698A (en) Obtaining a virus-like particle of the rabies virus in plants
AR078432A1 (en) METHOD FOR PREPARING SIMILAR PARTICLES TO VIRUSES (PSV) DERIVED FROM PLANTS
CL2011003271A1 (en) Polypeptide l1 of human papillomavirus (hpv) type 18 comprising at least one peptide comprising an epitope of a polypeptide l2; capsomer; virus-like particle (vlp); immunogenic composition; nucleic acid molecule; polypeptide; method of producing polypeptide; method for producing immunogenic composition.
MX370690B (en) New influenza virus immunizing epitope.
WO2016007576A3 (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
PH12020550266A1 (en) Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
WO2011109511A3 (en) Novel hiv-1 envelope glycoprotein
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
MX358883B (en) Increasing virus-like particle yield in plants.
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
CN103923743A (en) Extraction method for effective compositions of antrodia camphorata
EP2589604A4 (en) Truncated l1 protein of human papillomavirus type 52
JP2014521605A5 (en)
WO2023086415A3 (en) Vlp immunotherapy combined with ablation
WO2011080271A3 (en) Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof
CO2022011392A2 (en) hpv vaccine
MX2013013228A (en) Virus-like particles and process for preparing same.
JP2014519817A5 (en)
WO2016205641A3 (en) Respiratory syncytial virus having cleavage-resistant g protein and related materials and methods
JP2010235463A5 (en)
WO2012170125A3 (en) Algal produced malarial transmission blocking vaccines
BR112018000037A2 (en) recombinant virus-like particles using bovine immunodeficiency virus gag protein (bgag vlp), vaccine, transfer plasmid vector to produce bgag vlp, method for making bgag vlp, method for preparing the vaccine
EP3069730A3 (en) Soluble hiv-1 envelope glycoprotein trimers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22893577

Country of ref document: EP

Kind code of ref document: A2